Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second-line FOLFIRI with or without panitumumab after first-line FOLFOX + panitumumab in wild-type RAS metastatic colorectal cancer
2017-004519-38Phase 2Terminated
- Sponsor
- GEMCAD
- Start
- Apr 2018
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of panitumumab, irinotecan, folinic acid and fluorouracil in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by GEMCAD. Primary endpoint: 6-month progression-free survival. Started Apr 2018; status: terminated.
02
Drugs
panitumumabirinotecanfolinic acidfluorouracil
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2017-004519-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004519-38.